On January 12, 2021 BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, reported that a member of the senior management team is presenting at the following virtual conferences (Press release, BerGenBio, JAN 12, 2021, View Source [SID1234574333]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Solebury Trout Management Access Event. 6-15 January 2021

H.C. Wainwright Bioconnect 2021, 11-14 January 2021

SEB Virtual Nordic Healthcare Conference, 18-19 January 2021

Live presentation at 9.40am CET on 18 January

The presentations will be made available at www.bergenbio.com after the events.